Coronary Artery DiseaseNCT06327984
Barts Sex-CAD Database - Sex Hormones and Inflammatory Status in Coronary Artery Disease
An observational study of Coronary Artery Disease and Myocardial Infarction, run by Queen Mary University of London at 1 site in United Kingdom.
Trial summary
There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring up of the arteries of the heart - starts and progresses in women. In both men and women, CAD is the most common cause of heart attacks, which occur when the blood supply in the heart is interrupted (these are also… Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Coronary Artery Disease, Myocardial Infarction, Acute Coronary Syndrome
- How many people
- 6,000 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 21 Nov 2023to 31 Jan 2033
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients attending Barts Heart Centre with chest pain
Inclusion criteria Any patient presenting with chest pain ≥16 years old presenting to Barts Heart Centre will be included.
Exclusion criteria Patients <16 years old and Adults lacking capacity will be excluded. Patients where the cause of their chest pain presentation is not related to coronary artery disease e.g musculoskeletal chest pain, aortic dissection, gastrointestinal, pulmonary embolism
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Barts Health NHS Trust
London
Dr Krishnaraj Rathod
About this study
Official title: Barts Sex-CAD Database: Do Female Sex Hormone Levels Inform Inflammatory Status and Susceptibility in Women Suffering Coronary Artery Disease?
There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring up of the arteries of the heart - starts and progresses in women. In both men and women, CAD is the most common cause of heart attacks, which occur when the blood supply in the heart is interrupted (these are also known medically as 'acute coronary syndromes').
Before the menopause women appear to be protected from CAD; however, after the menopause that protection is lost. Also, those women who do suffer a heart attack have twice the risk of further heart attacks compared to men despite having the same treatment that works well in men. Biological differences between men and women are probably playing an important role in the way CAD develops. However, due to a lack of research there is currently little understanding of how the female body works in this area.
Read more
Inflammation is the body's natural response to injury or infection. Importantly it is also involved in the development of CAD. Hormones such as oestrogen and testosterone are also likely to be contributory factors. The investigators think the differences between the way these hormones and inflammation play a part in CAD in both men and women are important, but the role they play is not yet fully understood.
In this study the investigators wish to measure the 'markers' of inflammation in the blood of patients attending Barts Heart Centre with chest pain. The investigators will also conduct questionnaires with these patients, to understand their hormone status and how parts of their medical history may be a contributory factor. For patients who have previously attended Barts Heart Centre will will contact them to conduct the questionnaire over the telephone only. The investigators will combine this data with the data that is routinely collected during hospital admission. In this way the investigators hope to understand whether inflammation together with hormone status plays an important role in CAD. Our hope is that through this research the investigators will address an under researched area and find new ways of treating women and men with coronary artery disease.
Read the detailed description
- The investigators will collect data on sex hormone status (FSH, LH, oestradiol, progesterone and testosterone) of patients admitted to BHC. Data will subsequently be entered into a dedicated secure database by a member of the clinical team. A member of the clinical team will review hormone profiles and, if relevant abnormalities in hormone profiles are detected, appropriate follow up will be arranged for the patient. In addition, the following blood markers will also be extracted from the patients routine admission blood tests: Haemoglobin, white blood cell count, platelet count, haematocrit, neutrophil count, lymphocyte count, monocyte count, eosinophil count, coagulation results, d-dimer (if done), sodium, potassium, chloride, urea, creatinine, eGFR, bilirubin, ALT, ALP, protein, albumin, calcium, corrected calcium, phosphate, magnesium, troponin, hs-CRP. These data points will be logged in the secure database.
- We have composed a short questionnaire to examine aspects of patients' history relevant to their sex hormone status. For female patients this includes menstrual history, as well as relevant medications and medical conditions that may influence sex hormone status. For males an abbreviated form of the questionnaire includes relevant medications and medical conditions that my influence sex hormone status. This questionnaire will be delivered retrospectively to patients following their discharge from hospital. Clinical data has been gathered into the BartsREVASC database since 2016 therefore we aim to retrospectively include these patients and contact them via telephone to conduct the questionnaire only. Patients will be identified via the BartsREVASC database, and the electronic patient record and NHS Spine record will be checked to ensure the patient is still living and has appropriate capacity to consent. An text message will be sent to retrospective patients with provides a link to the study information and invitation letter which will advise that they will receive a phone call from a clinical member of the research team to conduct the questionnaire over the telephone. A telephone number for the research team will be provided if they wish to call us sooner at their own convenience to conduct the questionnaire rather than receive a call. We will obtain their verbal consent (which will be documented in a database) prior to proceeding with the questionnaire; data will be directly entered into the secure database. Questionnaires will be administered by a member of the clinical team who will also be responsible for entering the data into the database. In addition, we will consent patients to be contacted regarding future research studies examining sex differences in CAD and inflammation.
- Will seek also written consent from female and male patients prospectively included in this study during their hospital admission to obtain an additional blood test for specialised inflammatory profiling including but not limited to inflammatory cell count, white blood cell activation markers, markers of apoptosis, markers of cell death, inflammatory cytokine levels. These blood samples will be analysed at the William Harvey Research Institute, Queen Mary University of London using standard laboratory techniques. The investigators will also seek written consent from these patients to take part in the questionnaires outlined above for females and males. The questionnaires will be delivered in person at the time of blood sampling or over the telephone after discharge. In addition, the investigators will consent patients to be contacted regarding future research studies examining sex differences in CAD and inflammation. All data will be added to the secure database.
- In the circumstance where additional blood tests reveal significant results that require action. The investigators will inform the patient and the patients direct care team if applicable (e.g for current inpatients). If necessary, a referral to an appropriate specialist will be done with the patients consent. The investigators will also write to the patients' general practitioner in this circumstance to inform them of the results and action performed or required.
- Novel data held in the secure database will be cross analysed with routine clinical data from the BartsREVASC database, electronic patient record and other relevant databases if required such as the MINOCA database in order to establish relationships,for follow up and MACE outcome data (see below),. Protecting patient's data is important and therefore data will be pseudonymised before being used for research purposes.
- Patients will be followed up at 30 days/1 year/5years using electronic patient records at to determine outcomes including but not limited to medication data, all-cause mortality, readmission rates and further cardiovascular events.
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Acute Coronary Syndrome, Atherosclerosis, Inflammation
- Keywords
- Coronary artery disease, Acute coronary syndrome, Myocardial infarction, Sex characteristics, Hormones, Inflammation
- Medical subject headings
- Coronary Artery Disease, Myocardial Infarction, Acute Coronary Syndrome, Atherosclerosis, Inflammation
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Mortality at 30 days,1 year and 5 years, and relation to sex hormone/menstrual status/inflammatory profile
Measured: 30 days/1 year/5 years
Re-admission
Re-admission rates post revascularization and relation to sex hormone/menstrual status/inflammatory profile
Measured: 30 days/1 year/5 years
MACE
MACE post revascularisation and relation to sex hormone/menstrual status/inflammatory profile
Measured: 30 days/1 year/5 years
Secondary outcomes (2)
Relationship with specific MI types
Relationship of sex hormone/menstrual status/inflammatory profile with specific types of ACS such as MINOCA
Measured: 30 days/1 year/5 years
Relationship with inflammation
Relationship of sex hormone/menstrual status with markers of inflammation (e.g white cell count, CRP, D-dimer) and severity of disease (e.g troponin, extent of coronary disease)
Measured: 30 days/1 year/5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2024
- Study start21 Nov 2023
- Primary completion31 Jan 2033 (estimated)
- Study completion31 Jan 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Queen Mary University of LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 6,000 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Krishnaraj Rathod, MBBS PhD, Principal investigator, Queen Mary University of London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06327984
- Sponsor's protocol ID
- 157354
- Status last verified
- Sep 2026
- First submitted
- 18 Mar 2024
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Lee MT, Mahtta D, Ramsey DJ, Liu J, Misra A, Nasir K, Samad Z, Itchhaporia D, Khan SU, Schofield RS, Ballantyne CM, Petersen LA, Virani SS. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 Jul 1;6(7):782-790. doi: 10.1001/jamacardio.2021.0683.
PubMed 33881448Shabbir A, Rathod KS, Khambata RS, Ahluwalia A. Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:333-359. doi: 10.1146/annurev-pharmtox-010919-023229. Epub 2020 Oct 9.
PubMed 33035428Rathod KS, Jones DA, Jain AK, Lim P, MacCarthy PA, Rakhit R, Lockie T, Kalra S, Dalby MC, Malik IS, Whitbread M, Firoozi S, Bogle R, Redwood S, Cooper J, Gupta A, Lansky A, Wragg A, Mathur A, Ahluwalia A. The influence of biological age and sex on long-term outcome after percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiovasc Dis. 2021 Oct 25;11(5):659-678. eCollection 2021.
PubMed 34849299
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Barts Sex-CAD Database: Do Female Sex Hormone Levels Inform Inflammatory Status and Susceptibility in Women Suffering Coronary Artery Disease?
- ClinicalTrials.gov ID
- NCT06327984
- Acronym / sponsor ID
- 157354
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Acute Coronary Syndrome, Atherosclerosis, Inflammation
- Keywords
- Coronary artery disease, Acute coronary syndrome, Myocardial infarction, Sex characteristics, Hormones, Inflammation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 6,000 participants (estimated)
- Lead sponsor
- Queen Mary University of LondonUniversity, hospital or other
- Study start
- 21 Nov 2023 (actual)
- Primary completion
- 31 Jan 2033 (estimated)
- Study completion
- 31 Jan 2033 (estimated)
- First posted
- 25 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring up of the arteries of the heart - starts and progresses in women. In both men and women, CAD is the most common cause of heart attacks, which occur when the blood supply in the heart is interrupted (these are also known medically as 'acute coronary syndromes').
Before the menopause women appear to be protected from CAD; however, after the menopause that protection is lost. Also, those women who do suffer a heart attack have twice the risk of further heart attacks compared to men despite having the same treatment that works well in men. Biological differences between men and women are probably playing an important role in the way CAD develops. However, due to a lack of research there is currently little understanding of how the female body works in this area.
Inflammation is the body's natural response to injury or infection. Importantly it is also involved in the development of CAD. Hormones such as oestrogen and testosterone are also likely to be contributory factors. The investigators think the differences between the way these hormones and inflammation play a part in CAD in both men and women are important, but the role they play is not yet fully understood.
In this study the investigators wish to measure the 'markers' of inflammation in the blood of patients attending Barts Heart Centre with chest pain. The investigators will also conduct questionnaires with these patients, to understand their hormone status and how parts of their medical history may be a contributory factor. For patients who have previously attended Barts Heart Centre will will contact them to conduct the questionnaire over the telephone only. The investigators will combine this data with the data that is routinely collected during hospital admission. In this way the investigators hope to understand whether inflammation together with hormone status plays an important role in CAD. Our hope is that through this research the investigators will address an under researched area and find new ways of treating women and men with coronary artery disease.
Detailed description
- The investigators will collect data on sex hormone status (FSH, LH, oestradiol, progesterone and testosterone) of patients admitted to BHC. Data will subsequently be entered into a dedicated secure database by a member of the clinical team. A member of the clinical team will review hormone profiles and, if relevant abnormalities in hormone profiles are detected, appropriate follow up will be arranged for the patient. In addition, the following blood markers will also be extracted from the patients routine admission blood tests: Haemoglobin, white blood cell count, platelet count, haematocrit, neutrophil count, lymphocyte count, monocyte count, eosinophil count, coagulation results, d-dimer (if done), sodium, potassium, chloride, urea, creatinine, eGFR, bilirubin, ALT, ALP, protein, albumin, calcium, corrected calcium, phosphate, magnesium, troponin, hs-CRP. These data points will be logged in the secure database.
- We have composed a short questionnaire to examine aspects of patients' history relevant to their sex hormone status. For female patients this includes menstrual history, as well as relevant medications and medical conditions that may influence sex hormone status. For males an abbreviated form of the questionnaire includes relevant medications and medical conditions that my influence sex hormone status. This questionnaire will be delivered retrospectively to patients following their discharge from hospital. Clinical data has been gathered into the BartsREVASC database since 2016 therefore we aim to retrospectively include these patients and contact them via telephone to conduct the questionnaire only. Patients will be identified via the BartsREVASC database, and the electronic patient record and NHS Spine record will be checked to ensure the patient is still living and has appropriate capacity to consent. An text message will be sent to retrospective patients with provides a link to the study information and invitation letter which will advise that they will receive a phone call from a clinical member of the research team to conduct the questionnaire over the telephone. A telephone number for the research team will be provided if they wish to call us sooner at their own convenience to conduct the questionnaire rather than receive a call. We will obtain their verbal consent (which will be documented in a database) prior to proceeding with the questionnaire; data will be directly entered into the secure database. Questionnaires will be administered by a member of the clinical team who will also be responsible for entering the data into the database. In addition, we will consent patients to be contacted regarding future research studies examining sex differences in CAD and inflammation.
- Will seek also written consent from female and male patients prospectively included in this study during their hospital admission to obtain an additional blood test for specialised inflammatory profiling including but not limited to inflammatory cell count, white blood cell activation markers, markers of apoptosis, markers of cell death, inflammatory cytokine levels. These blood samples will be analysed at the William Harvey Research Institute, Queen Mary University of London using standard laboratory techniques. The investigators will also seek written consent from these patients to take part in the questionnaires outlined above for females and males. The questionnaires will be delivered in person at the time of blood sampling or over the telephone after discharge. In addition, the investigators will consent patients to be contacted regarding future research studies examining sex differences in CAD and inflammation. All data will be added to the secure database.
- In the circumstance where additional blood tests reveal significant results that require action. The investigators will inform the patient and the patients direct care team if applicable (e.g for current inpatients). If necessary, a referral to an appropriate specialist will be done with the patients consent. The investigators will also write to the patients' general practitioner in this circumstance to inform them of the results and action performed or required.
- Novel data held in the secure database will be cross analysed with routine clinical data from the BartsREVASC database, electronic patient record and other relevant databases if required such as the MINOCA database in order to establish relationships,for follow up and MACE outcome data (see below),. Protecting patient's data is important and therefore data will be pseudonymised before being used for research purposes.
- Patients will be followed up at 30 days/1 year/5years using electronic patient records at to determine outcomes including but not limited to medication data, all-cause mortality, readmission rates and further cardiovascular events.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients attending Barts Heart Centre with chest pain
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mortality
Time frame: 30 days/1 year/5 years
Mortality at 30 days,1 year and 5 years, and relation to sex hormone/menstrual status/inflammatory profile
Re-admission
Time frame: 30 days/1 year/5 years
Re-admission rates post revascularization and relation to sex hormone/menstrual status/inflammatory profile
MACE
Time frame: 30 days/1 year/5 years
MACE post revascularisation and relation to sex hormone/menstrual status/inflammatory profile
2 secondary outcomes
Relationship with specific MI types
Time frame: 30 days/1 year/5 years
Relationship with inflammation
Time frame: 30 days/1 year/5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
- Background: PubMed 33881448Lee MT, Mahtta D, Ramsey DJ, Liu J, Misra A, Nasir K, Samad Z, Itchhaporia D, Khan SU, Schofield RS, Ballantyne CM, Petersen LA, Virani SS. Sex-Related Disparities in Cardiovascular Health Care Among Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2021 Jul 1;6(7):782-790. doi: 10.1001/jamacardio.2021.0683.
- Background: PubMed 33035428Shabbir A, Rathod KS, Khambata RS, Ahluwalia A. Sex Differences in the Inflammatory Response: Pharmacological Opportunities for Therapeutics for Coronary Artery Disease. Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:333-359. doi: 10.1146/annurev-pharmtox-010919-023229. Epub 2020 Oct 9.
- Results publication: PubMed 34849299Rathod KS, Jones DA, Jain AK, Lim P, MacCarthy PA, Rakhit R, Lockie T, Kalra S, Dalby MC, Malik IS, Whitbread M, Firoozi S, Bogle R, Redwood S, Cooper J, Gupta A, Lansky A, Wragg A, Mathur A, Ahluwalia A. The influence of biological age and sex on long-term outcome after percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiovasc Dis. 2021 Oct 25;11(5):659-678. eCollection 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Krishnaraj Rathod, MBBS PhD principal investigator
Queen Mary University of London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease and Myocardial Infarction, run by Queen Mary University of London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Krishnaraj Rathod, MBBS PhD (020 7882 5720, k.s.rathod@qmul.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: 30 days/1 year/5 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06327984, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.